Zinc sulphate attenuates metabolic dysfunctions induced by olanzapine via the reduction of insulin resistance, hepatic oxidative stress, and inflammation in albino rats Article Swipe
Samir A. E. Bashandy
,
Rasha E. Mostafa
,
Marawan A. Elbaset
,
Fatma Ibrahim
,
Fatma A. Morsy
,
Omar A. Ahmed‐Farid
,
Hassan Ibrahim
,
Bassim M. S. A. Mohamed
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1186/s40360-025-00889-0
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1186/s40360-025-00889-0
Olanzapine, an atypical antipsychotic drug, is used to treat psychological diseases. However, it’s use carries common side effects. Those include weight gain, dyslipidemia, elevated glucose levels, and disrupted oxidative balance. We aimed to test the effect of zinc coadministration to lessen metabolic disturbances, inflammation and oxidative stress in a rat model. Four treatment groups ( n = 6) were involved in this investigation. Group 1 was the control group (received no intervention). Group 2 received olanzapine (10 mg/kg, p.o.; daily) for six weeks, whereas Groups 3 and 4 received 50 mg/kg and 100 mg/kg of zinc sulphate (ZnSO 4 ,p.o.; daily) respectively, in addition to olanzapine (10 mg/kg p.o.; daily). Following treatment completion, group 2 showed increased levels of stress markers (GSSG, MDA, and NO) and impaired levels of antioxidant markers (CAT, SOD, and GSH). Further, a strong positive correlation between insulin resistance index (HOMA-IR) and IL-6, TNF-α, and MDA of liver. Insulin resistance is a possible manifestation of the oxidative stress burden and the widespread inflammatory environment. In groups 3 and 4, however, ZnSO 4 recovered each of these markers in a dose-dependent manner. Improvements were also noted in other homeostatic markers, such as taurine, coenzyme Q10, ascorbic acid, and vitamin E. Remarkably, in both combination groups, there was a significant improvement in all metabolic indicators of dyslipidemia (triglycerides, total cholesterol) and insulin resistance index. The biochemical study and the histological assessment of the liver slices agreed with the results. Thus, the results clearly suggest that Zinc supplementation can significantly improve oxidative stress, inflammation, metabolic perturbation (dyslipidemia and insulin resistance), and liver injury caused by olanzapine in Albino rats.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1186/s40360-025-00889-0
- OA Status
- gold
- Cited By
- 1
- References
- 47
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4409433184
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4409433184Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1186/s40360-025-00889-0Digital Object Identifier
- Title
-
Zinc sulphate attenuates metabolic dysfunctions induced by olanzapine via the reduction of insulin resistance, hepatic oxidative stress, and inflammation in albino ratsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-04-14Full publication date if available
- Authors
-
Samir A. E. Bashandy, Rasha E. Mostafa, Marawan A. Elbaset, Fatma Ibrahim, Fatma A. Morsy, Omar A. Ahmed‐Farid, Hassan Ibrahim, Bassim M. S. A. MohamedList of authors in order
- Landing page
-
https://doi.org/10.1186/s40360-025-00889-0Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1186/s40360-025-00889-0Direct OA link when available
- Concepts
-
Oxidative stress, Insulin resistance, Internal medicine, Endocrinology, Dyslipidemia, Medicine, Lipid profile, Olanzapine, Coenzyme Q10, Insulin, Pharmacology, Chemistry, Cholesterol, Diabetes mellitus, Schizophrenia (object-oriented programming), PsychiatryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- References (count)
-
47Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4409433184 |
|---|---|
| doi | https://doi.org/10.1186/s40360-025-00889-0 |
| ids.doi | https://doi.org/10.1186/s40360-025-00889-0 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40229885 |
| ids.openalex | https://openalex.org/W4409433184 |
| fwci | 4.55217148 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | Q000187 |
| mesh[1].descriptor_ui | D018384 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | drug effects |
| mesh[1].descriptor_name | Oxidative Stress |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D007333 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Insulin Resistance |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D000077152 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Olanzapine |
| mesh[4].qualifier_ui | Q000187 |
| mesh[4].descriptor_ui | D008099 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | drug effects |
| mesh[4].descriptor_name | Liver |
| mesh[5].qualifier_ui | Q000378 |
| mesh[5].descriptor_ui | D008099 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | metabolism |
| mesh[5].descriptor_name | Liver |
| mesh[6].qualifier_ui | Q000473 |
| mesh[6].descriptor_ui | D008099 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | pathology |
| mesh[6].descriptor_name | Liver |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D008297 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Male |
| mesh[8].qualifier_ui | Q000494 |
| mesh[8].descriptor_ui | D019287 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | pharmacology |
| mesh[8].descriptor_name | Zinc Sulfate |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D019287 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Zinc Sulfate |
| mesh[10].qualifier_ui | Q000188 |
| mesh[10].descriptor_ui | D007249 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | drug therapy |
| mesh[10].descriptor_name | Inflammation |
| mesh[11].qualifier_ui | Q000378 |
| mesh[11].descriptor_ui | D007249 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | metabolism |
| mesh[11].descriptor_name | Inflammation |
| mesh[12].qualifier_ui | Q000139 |
| mesh[12].descriptor_ui | D007249 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | chemically induced |
| mesh[12].descriptor_name | Inflammation |
| mesh[13].qualifier_ui | Q000633 |
| mesh[13].descriptor_ui | D014150 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | toxicity |
| mesh[13].descriptor_name | Antipsychotic Agents |
| mesh[14].qualifier_ui | Q000009 |
| mesh[14].descriptor_ui | D014150 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | adverse effects |
| mesh[14].descriptor_name | Antipsychotic Agents |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D017208 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Rats, Wistar |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D051381 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Rats |
| mesh[17].qualifier_ui | Q000494 |
| mesh[17].descriptor_ui | D000975 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | pharmacology |
| mesh[17].descriptor_name | Antioxidants |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D000818 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Animals |
| mesh[19].qualifier_ui | Q000187 |
| mesh[19].descriptor_ui | D018384 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | drug effects |
| mesh[19].descriptor_name | Oxidative Stress |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D007333 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Insulin Resistance |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D000077152 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Olanzapine |
| mesh[22].qualifier_ui | Q000187 |
| mesh[22].descriptor_ui | D008099 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | drug effects |
| mesh[22].descriptor_name | Liver |
| mesh[23].qualifier_ui | Q000378 |
| mesh[23].descriptor_ui | D008099 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | metabolism |
| mesh[23].descriptor_name | Liver |
| mesh[24].qualifier_ui | Q000473 |
| mesh[24].descriptor_ui | D008099 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | pathology |
| mesh[24].descriptor_name | Liver |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D008297 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Male |
| mesh[26].qualifier_ui | Q000494 |
| mesh[26].descriptor_ui | D019287 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | pharmacology |
| mesh[26].descriptor_name | Zinc Sulfate |
| mesh[27].qualifier_ui | Q000627 |
| mesh[27].descriptor_ui | D019287 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | therapeutic use |
| mesh[27].descriptor_name | Zinc Sulfate |
| mesh[28].qualifier_ui | Q000188 |
| mesh[28].descriptor_ui | D007249 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | drug therapy |
| mesh[28].descriptor_name | Inflammation |
| mesh[29].qualifier_ui | Q000378 |
| mesh[29].descriptor_ui | D007249 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | metabolism |
| mesh[29].descriptor_name | Inflammation |
| mesh[30].qualifier_ui | Q000139 |
| mesh[30].descriptor_ui | D007249 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | chemically induced |
| mesh[30].descriptor_name | Inflammation |
| mesh[31].qualifier_ui | Q000633 |
| mesh[31].descriptor_ui | D014150 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | toxicity |
| mesh[31].descriptor_name | Antipsychotic Agents |
| mesh[32].qualifier_ui | Q000009 |
| mesh[32].descriptor_ui | D014150 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | adverse effects |
| mesh[32].descriptor_name | Antipsychotic Agents |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D017208 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Rats, Wistar |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D051381 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Rats |
| mesh[35].qualifier_ui | Q000494 |
| mesh[35].descriptor_ui | D000975 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | pharmacology |
| mesh[35].descriptor_name | Antioxidants |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D000818 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Animals |
| mesh[37].qualifier_ui | Q000187 |
| mesh[37].descriptor_ui | D018384 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | drug effects |
| mesh[37].descriptor_name | Oxidative Stress |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D007333 |
| mesh[38].is_major_topic | True |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Insulin Resistance |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D000077152 |
| mesh[39].is_major_topic | True |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Olanzapine |
| mesh[40].qualifier_ui | Q000187 |
| mesh[40].descriptor_ui | D008099 |
| mesh[40].is_major_topic | True |
| mesh[40].qualifier_name | drug effects |
| mesh[40].descriptor_name | Liver |
| mesh[41].qualifier_ui | Q000378 |
| mesh[41].descriptor_ui | D008099 |
| mesh[41].is_major_topic | True |
| mesh[41].qualifier_name | metabolism |
| mesh[41].descriptor_name | Liver |
| mesh[42].qualifier_ui | Q000473 |
| mesh[42].descriptor_ui | D008099 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | pathology |
| mesh[42].descriptor_name | Liver |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D008297 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Male |
| mesh[44].qualifier_ui | Q000494 |
| mesh[44].descriptor_ui | D019287 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | pharmacology |
| mesh[44].descriptor_name | Zinc Sulfate |
| mesh[45].qualifier_ui | Q000627 |
| mesh[45].descriptor_ui | D019287 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | therapeutic use |
| mesh[45].descriptor_name | Zinc Sulfate |
| mesh[46].qualifier_ui | Q000188 |
| mesh[46].descriptor_ui | D007249 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | drug therapy |
| mesh[46].descriptor_name | Inflammation |
| mesh[47].qualifier_ui | Q000378 |
| mesh[47].descriptor_ui | D007249 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | metabolism |
| mesh[47].descriptor_name | Inflammation |
| mesh[48].qualifier_ui | Q000139 |
| mesh[48].descriptor_ui | D007249 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | chemically induced |
| mesh[48].descriptor_name | Inflammation |
| mesh[49].qualifier_ui | Q000633 |
| mesh[49].descriptor_ui | D014150 |
| mesh[49].is_major_topic | True |
| mesh[49].qualifier_name | toxicity |
| mesh[49].descriptor_name | Antipsychotic Agents |
| type | article |
| title | Zinc sulphate attenuates metabolic dysfunctions induced by olanzapine via the reduction of insulin resistance, hepatic oxidative stress, and inflammation in albino rats |
| biblio.issue | 1 |
| biblio.volume | 26 |
| biblio.last_page | 84 |
| biblio.first_page | 84 |
| topics[0].id | https://openalex.org/T12494 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9957000017166138 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2728 |
| topics[0].subfield.display_name | Neurology |
| topics[0].display_name | Alcoholism and Thiamine Deficiency |
| topics[1].id | https://openalex.org/T12229 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9936000108718872 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2735 |
| topics[1].subfield.display_name | Pediatrics, Perinatology and Child Health |
| topics[1].display_name | Pharmacological Effects and Toxicity Studies |
| topics[2].id | https://openalex.org/T12533 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.992900013923645 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1307 |
| topics[2].subfield.display_name | Cell Biology |
| topics[2].display_name | Aldose Reductase and Taurine |
| is_xpac | False |
| apc_list.value | 1690 |
| apc_list.currency | GBP |
| apc_list.value_usd | 2072 |
| apc_paid.value | 1690 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 2072 |
| concepts[0].id | https://openalex.org/C2776151105 |
| concepts[0].level | 2 |
| concepts[0].score | 0.7755463719367981 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q898814 |
| concepts[0].display_name | Oxidative stress |
| concepts[1].id | https://openalex.org/C2777391703 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7698580622673035 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1053470 |
| concepts[1].display_name | Insulin resistance |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.7342755198478699 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C134018914 |
| concepts[3].level | 1 |
| concepts[3].score | 0.7073355913162231 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[3].display_name | Endocrinology |
| concepts[4].id | https://openalex.org/C2778096610 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6206350326538086 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1476525 |
| concepts[4].display_name | Dyslipidemia |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.4634101092815399 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C2778270857 |
| concepts[6].level | 3 |
| concepts[6].score | 0.41575708985328674 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q2723972 |
| concepts[6].display_name | Lipid profile |
| concepts[7].id | https://openalex.org/C2776619155 |
| concepts[7].level | 3 |
| concepts[7].score | 0.414450466632843 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q201872 |
| concepts[7].display_name | Olanzapine |
| concepts[8].id | https://openalex.org/C2779384338 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4144023656845093 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q321285 |
| concepts[8].display_name | Coenzyme Q10 |
| concepts[9].id | https://openalex.org/C2779306644 |
| concepts[9].level | 2 |
| concepts[9].score | 0.38397735357284546 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2002370 |
| concepts[9].display_name | Insulin |
| concepts[10].id | https://openalex.org/C98274493 |
| concepts[10].level | 1 |
| concepts[10].score | 0.355296790599823 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[10].display_name | Pharmacology |
| concepts[11].id | https://openalex.org/C185592680 |
| concepts[11].level | 0 |
| concepts[11].score | 0.35310986638069153 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[11].display_name | Chemistry |
| concepts[12].id | https://openalex.org/C2778163477 |
| concepts[12].level | 2 |
| concepts[12].score | 0.278251051902771 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q43656 |
| concepts[12].display_name | Cholesterol |
| concepts[13].id | https://openalex.org/C555293320 |
| concepts[13].level | 2 |
| concepts[13].score | 0.22939899563789368 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[13].display_name | Diabetes mellitus |
| concepts[14].id | https://openalex.org/C2776412080 |
| concepts[14].level | 2 |
| concepts[14].score | 0.1335669755935669 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7431605 |
| concepts[14].display_name | Schizophrenia (object-oriented programming) |
| concepts[15].id | https://openalex.org/C118552586 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7867 |
| concepts[15].display_name | Psychiatry |
| keywords[0].id | https://openalex.org/keywords/oxidative-stress |
| keywords[0].score | 0.7755463719367981 |
| keywords[0].display_name | Oxidative stress |
| keywords[1].id | https://openalex.org/keywords/insulin-resistance |
| keywords[1].score | 0.7698580622673035 |
| keywords[1].display_name | Insulin resistance |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.7342755198478699 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/endocrinology |
| keywords[3].score | 0.7073355913162231 |
| keywords[3].display_name | Endocrinology |
| keywords[4].id | https://openalex.org/keywords/dyslipidemia |
| keywords[4].score | 0.6206350326538086 |
| keywords[4].display_name | Dyslipidemia |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.4634101092815399 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/lipid-profile |
| keywords[6].score | 0.41575708985328674 |
| keywords[6].display_name | Lipid profile |
| keywords[7].id | https://openalex.org/keywords/olanzapine |
| keywords[7].score | 0.414450466632843 |
| keywords[7].display_name | Olanzapine |
| keywords[8].id | https://openalex.org/keywords/coenzyme-q10 |
| keywords[8].score | 0.4144023656845093 |
| keywords[8].display_name | Coenzyme Q10 |
| keywords[9].id | https://openalex.org/keywords/insulin |
| keywords[9].score | 0.38397735357284546 |
| keywords[9].display_name | Insulin |
| keywords[10].id | https://openalex.org/keywords/pharmacology |
| keywords[10].score | 0.355296790599823 |
| keywords[10].display_name | Pharmacology |
| keywords[11].id | https://openalex.org/keywords/chemistry |
| keywords[11].score | 0.35310986638069153 |
| keywords[11].display_name | Chemistry |
| keywords[12].id | https://openalex.org/keywords/cholesterol |
| keywords[12].score | 0.278251051902771 |
| keywords[12].display_name | Cholesterol |
| keywords[13].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[13].score | 0.22939899563789368 |
| keywords[13].display_name | Diabetes mellitus |
| keywords[14].id | https://openalex.org/keywords/schizophrenia |
| keywords[14].score | 0.1335669755935669 |
| keywords[14].display_name | Schizophrenia (object-oriented programming) |
| language | en |
| locations[0].id | doi:10.1186/s40360-025-00889-0 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S29101735 |
| locations[0].source.issn | 2050-6511 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2050-6511 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | BMC Pharmacology and Toxicology |
| locations[0].source.host_organization | https://openalex.org/P4310320256 |
| locations[0].source.host_organization_name | BioMed Central |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320256, https://openalex.org/P4310319965 |
| locations[0].source.host_organization_lineage_names | BioMed Central, Springer Nature |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | BMC Pharmacology and Toxicology |
| locations[0].landing_page_url | https://doi.org/10.1186/s40360-025-00889-0 |
| locations[1].id | pmid:40229885 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | BMC pharmacology & toxicology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40229885 |
| locations[2].id | pmh:oai:europepmc.org:10809863 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11998154 |
| locations[3].id | pmh:oai:scholarworks.indianapolis.iu.edu:1805/48240 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306522653 |
| locations[3].source.issn | |
| locations[3].source.type | journal |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | True |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PMC |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].license | cc-by |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Article |
| locations[3].license_id | https://openalex.org/licenses/cc-by |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | PMC |
| locations[3].landing_page_url | https://hdl.handle.net/1805/48240 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5074443830 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5701-0320 |
| authorships[0].author.display_name | Samir A. E. Bashandy |
| authorships[0].countries | EG |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210131959 |
| authorships[0].affiliations[0].raw_affiliation_string | Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. [email protected]. |
| authorships[0].institutions[0].id | https://openalex.org/I4210131959 |
| authorships[0].institutions[0].ror | https://ror.org/02n85j827 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210131959 |
| authorships[0].institutions[0].country_code | EG |
| authorships[0].institutions[0].display_name | National Research Centre |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Samir A E Bashandy |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. [email protected]. |
| authorships[1].author.id | https://openalex.org/A5051389286 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5765-350X |
| authorships[1].author.display_name | Rasha E. Mostafa |
| authorships[1].countries | EG |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210131959 |
| authorships[1].affiliations[0].raw_affiliation_string | Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. |
| authorships[1].institutions[0].id | https://openalex.org/I4210131959 |
| authorships[1].institutions[0].ror | https://ror.org/02n85j827 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210131959 |
| authorships[1].institutions[0].country_code | EG |
| authorships[1].institutions[0].display_name | National Research Centre |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Rasha E Mostafa |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. |
| authorships[2].author.id | https://openalex.org/A5039718142 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-0861-6251 |
| authorships[2].author.display_name | Marawan A. Elbaset |
| authorships[2].countries | EG, US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I55769427 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Neurology and Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA. |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I4210131959 |
| authorships[2].affiliations[1].raw_affiliation_string | Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. |
| authorships[2].institutions[0].id | https://openalex.org/I4210131959 |
| authorships[2].institutions[0].ror | https://ror.org/02n85j827 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210131959 |
| authorships[2].institutions[0].country_code | EG |
| authorships[2].institutions[0].display_name | National Research Centre |
| authorships[2].institutions[1].id | https://openalex.org/I55769427 |
| authorships[2].institutions[1].ror | https://ror.org/05gxnyn08 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I55769427, https://openalex.org/I592451 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | Indiana University – Purdue University Indianapolis |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Marawan A El-Baset |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Neurology and Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA., Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. |
| authorships[3].author.id | https://openalex.org/A5101477444 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-0011-9389 |
| authorships[3].author.display_name | Fatma Ibrahim |
| authorships[3].countries | EG |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210131959 |
| authorships[3].affiliations[0].raw_affiliation_string | Biochemistry Department, Biotechnology Research Institute, National Research Centre, 33 El- Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. |
| authorships[3].institutions[0].id | https://openalex.org/I4210131959 |
| authorships[3].institutions[0].ror | https://ror.org/02n85j827 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210131959 |
| authorships[3].institutions[0].country_code | EG |
| authorships[3].institutions[0].display_name | National Research Centre |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Fatma A A Ibrahim |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Biochemistry Department, Biotechnology Research Institute, National Research Centre, 33 El- Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. |
| authorships[4].author.id | https://openalex.org/A5013392061 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-6109-5670 |
| authorships[4].author.display_name | Fatma A. Morsy |
| authorships[4].countries | EG |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210131959 |
| authorships[4].affiliations[0].raw_affiliation_string | Pathology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. |
| authorships[4].institutions[0].id | https://openalex.org/I4210131959 |
| authorships[4].institutions[0].ror | https://ror.org/02n85j827 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210131959 |
| authorships[4].institutions[0].country_code | EG |
| authorships[4].institutions[0].display_name | National Research Centre |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Fatma A Morsy |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Pathology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. |
| authorships[5].author.id | https://openalex.org/A5046526118 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-1020-5777 |
| authorships[5].author.display_name | Omar A. Ahmed‐Farid |
| authorships[5].countries | EG |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210136593 |
| authorships[5].affiliations[0].raw_affiliation_string | Physiology Department, National Organization for Drug Control and Research, Cairo, Egypt. |
| authorships[5].institutions[0].id | https://openalex.org/I4210136593 |
| authorships[5].institutions[0].ror | https://ror.org/0407ex783 |
| authorships[5].institutions[0].type | facility |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210136593, https://openalex.org/I4210160667 |
| authorships[5].institutions[0].country_code | EG |
| authorships[5].institutions[0].display_name | National Organization for Drug Control and Research |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Omar A Farid |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Physiology Department, National Organization for Drug Control and Research, Cairo, Egypt. |
| authorships[6].author.id | https://openalex.org/A5013104887 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-1018-9532 |
| authorships[6].author.display_name | Hassan Ibrahim |
| authorships[6].countries | EG |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210136593 |
| authorships[6].affiliations[0].raw_affiliation_string | Physiology Department, National Organization for Drug Control and Research, Cairo, Egypt. |
| authorships[6].institutions[0].id | https://openalex.org/I4210136593 |
| authorships[6].institutions[0].ror | https://ror.org/0407ex783 |
| authorships[6].institutions[0].type | facility |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210136593, https://openalex.org/I4210160667 |
| authorships[6].institutions[0].country_code | EG |
| authorships[6].institutions[0].display_name | National Organization for Drug Control and Research |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Halima M Ibrahim |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Physiology Department, National Organization for Drug Control and Research, Cairo, Egypt. |
| authorships[7].author.id | https://openalex.org/A5054049770 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-0536-8261 |
| authorships[7].author.display_name | Bassim M. S. A. Mohamed |
| authorships[7].countries | EG |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210131959 |
| authorships[7].affiliations[0].raw_affiliation_string | Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. [email protected]. |
| authorships[7].institutions[0].id | https://openalex.org/I4210131959 |
| authorships[7].institutions[0].ror | https://ror.org/02n85j827 |
| authorships[7].institutions[0].type | facility |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210131959 |
| authorships[7].institutions[0].country_code | EG |
| authorships[7].institutions[0].display_name | National Research Centre |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Bassim M S A Mohamed |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Bohouth St., Dokki, P.O. 12622, Cairo, Egypt. [email protected]. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1186/s40360-025-00889-0 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Zinc sulphate attenuates metabolic dysfunctions induced by olanzapine via the reduction of insulin resistance, hepatic oxidative stress, and inflammation in albino rats |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12494 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9957000017166138 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2728 |
| primary_topic.subfield.display_name | Neurology |
| primary_topic.display_name | Alcoholism and Thiamine Deficiency |
| related_works | https://openalex.org/W3199814457, https://openalex.org/W4220837484, https://openalex.org/W4319589812, https://openalex.org/W4307686915, https://openalex.org/W3122060348, https://openalex.org/W4392155425, https://openalex.org/W2954406487, https://openalex.org/W3017172007, https://openalex.org/W2073817778, https://openalex.org/W2770835749 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1186/s40360-025-00889-0 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S29101735 |
| best_oa_location.source.issn | 2050-6511 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2050-6511 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | BMC Pharmacology and Toxicology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320256 |
| best_oa_location.source.host_organization_name | BioMed Central |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320256, https://openalex.org/P4310319965 |
| best_oa_location.source.host_organization_lineage_names | BioMed Central, Springer Nature |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | BMC Pharmacology and Toxicology |
| best_oa_location.landing_page_url | https://doi.org/10.1186/s40360-025-00889-0 |
| primary_location.id | doi:10.1186/s40360-025-00889-0 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S29101735 |
| primary_location.source.issn | 2050-6511 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2050-6511 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | BMC Pharmacology and Toxicology |
| primary_location.source.host_organization | https://openalex.org/P4310320256 |
| primary_location.source.host_organization_name | BioMed Central |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320256, https://openalex.org/P4310319965 |
| primary_location.source.host_organization_lineage_names | BioMed Central, Springer Nature |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | BMC Pharmacology and Toxicology |
| primary_location.landing_page_url | https://doi.org/10.1186/s40360-025-00889-0 |
| publication_date | 2025-04-14 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2164694650, https://openalex.org/W3112257502, https://openalex.org/W3177351253, https://openalex.org/W2230556265, https://openalex.org/W2790218348, https://openalex.org/W1947757731, https://openalex.org/W2992654899, https://openalex.org/W2144576542, https://openalex.org/W2757211655, https://openalex.org/W4327766729, https://openalex.org/W2795108790, https://openalex.org/W4388461418, https://openalex.org/W3130950753, https://openalex.org/W4405239750, https://openalex.org/W4295429480, https://openalex.org/W4386603606, https://openalex.org/W4390792440, https://openalex.org/W4391145816, https://openalex.org/W2042784458, https://openalex.org/W2088392349, https://openalex.org/W2061342459, https://openalex.org/W1968094894, https://openalex.org/W2167543749, https://openalex.org/W3026957400, https://openalex.org/W2054667494, https://openalex.org/W4399654809, https://openalex.org/W2804567710, https://openalex.org/W2972718084, https://openalex.org/W1902796268, https://openalex.org/W4284710058, https://openalex.org/W2406572192, https://openalex.org/W2562179245, https://openalex.org/W3096623767, https://openalex.org/W4294495185, https://openalex.org/W3217240232, https://openalex.org/W2999209781, https://openalex.org/W2963161528, https://openalex.org/W4394989893, https://openalex.org/W4388017767, https://openalex.org/W3199726259, https://openalex.org/W2052786908, https://openalex.org/W4292664210, https://openalex.org/W2914092144, https://openalex.org/W3027726841, https://openalex.org/W3110898472, https://openalex.org/W4210527197, https://openalex.org/W2087430872 |
| referenced_works_count | 47 |
| abstract_inverted_index.( | 55 |
| abstract_inverted_index.1 | 65 |
| abstract_inverted_index.2 | 74, 115 |
| abstract_inverted_index.3 | 86, 171 |
| abstract_inverted_index.4 | 88, 99, 176 |
| abstract_inverted_index.= | 57 |
| abstract_inverted_index.a | 49, 137, 156, 183, 211 |
| abstract_inverted_index.n | 56 |
| abstract_inverted_index.4, | 173 |
| abstract_inverted_index.50 | 90 |
| abstract_inverted_index.6) | 58 |
| abstract_inverted_index.E. | 203 |
| abstract_inverted_index.In | 169 |
| abstract_inverted_index.We | 31 |
| abstract_inverted_index.an | 2 |
| abstract_inverted_index.as | 195 |
| abstract_inverted_index.by | 266 |
| abstract_inverted_index.in | 48, 61, 103, 182, 190, 205, 214, 268 |
| abstract_inverted_index.is | 6, 155 |
| abstract_inverted_index.no | 71 |
| abstract_inverted_index.of | 37, 95, 119, 129, 151, 159, 179, 218, 234 |
| abstract_inverted_index.to | 8, 33, 40, 105 |
| abstract_inverted_index.(10 | 77, 107 |
| abstract_inverted_index.100 | 93 |
| abstract_inverted_index.MDA | 150 |
| abstract_inverted_index.NO) | 125 |
| abstract_inverted_index.The | 227 |
| abstract_inverted_index.all | 215 |
| abstract_inverted_index.and | 27, 45, 87, 92, 124, 126, 134, 146, 149, 164, 172, 201, 223, 230, 259, 262 |
| abstract_inverted_index.can | 250 |
| abstract_inverted_index.for | 81 |
| abstract_inverted_index.rat | 50 |
| abstract_inverted_index.six | 82 |
| abstract_inverted_index.the | 35, 67, 160, 165, 231, 235, 240, 243 |
| abstract_inverted_index.use | 14 |
| abstract_inverted_index.was | 66, 210 |
| abstract_inverted_index.Four | 52 |
| abstract_inverted_index.MDA, | 123 |
| abstract_inverted_index.Q10, | 198 |
| abstract_inverted_index.SOD, | 133 |
| abstract_inverted_index.Zinc | 248 |
| abstract_inverted_index.ZnSO | 175 |
| abstract_inverted_index.also | 188 |
| abstract_inverted_index.both | 206 |
| abstract_inverted_index.each | 178 |
| abstract_inverted_index.side | 17 |
| abstract_inverted_index.such | 194 |
| abstract_inverted_index.test | 34 |
| abstract_inverted_index.that | 247 |
| abstract_inverted_index.this | 62 |
| abstract_inverted_index.used | 7 |
| abstract_inverted_index.were | 59, 187 |
| abstract_inverted_index.with | 239 |
| abstract_inverted_index.zinc | 38, 96 |
| abstract_inverted_index.(CAT, | 132 |
| abstract_inverted_index.(ZnSO | 98 |
| abstract_inverted_index.GSH). | 135 |
| abstract_inverted_index.Group | 64, 73 |
| abstract_inverted_index.IL-6, | 147 |
| abstract_inverted_index.Those | 19 |
| abstract_inverted_index.Thus, | 242 |
| abstract_inverted_index.acid, | 200 |
| abstract_inverted_index.aimed | 32 |
| abstract_inverted_index.drug, | 5 |
| abstract_inverted_index.gain, | 22 |
| abstract_inverted_index.group | 69, 114 |
| abstract_inverted_index.index | 144 |
| abstract_inverted_index.liver | 236, 263 |
| abstract_inverted_index.mg/kg | 91, 94, 108 |
| abstract_inverted_index.noted | 189 |
| abstract_inverted_index.other | 191 |
| abstract_inverted_index.p.o.; | 79, 109 |
| abstract_inverted_index.rats. | 270 |
| abstract_inverted_index.study | 229 |
| abstract_inverted_index.there | 209 |
| abstract_inverted_index.these | 180 |
| abstract_inverted_index.total | 221 |
| abstract_inverted_index.treat | 9 |
| abstract_inverted_index.(GSSG, | 122 |
| abstract_inverted_index.,p.o.; | 100 |
| abstract_inverted_index.Albino | 269 |
| abstract_inverted_index.Groups | 85 |
| abstract_inverted_index.agreed | 238 |
| abstract_inverted_index.burden | 163 |
| abstract_inverted_index.caused | 265 |
| abstract_inverted_index.common | 16 |
| abstract_inverted_index.daily) | 80, 101 |
| abstract_inverted_index.effect | 36 |
| abstract_inverted_index.groups | 54, 170 |
| abstract_inverted_index.index. | 226 |
| abstract_inverted_index.injury | 264 |
| abstract_inverted_index.it’s | 13 |
| abstract_inverted_index.lessen | 41 |
| abstract_inverted_index.levels | 118, 128 |
| abstract_inverted_index.liver. | 152 |
| abstract_inverted_index.mg/kg, | 78 |
| abstract_inverted_index.model. | 51 |
| abstract_inverted_index.showed | 116 |
| abstract_inverted_index.slices | 237 |
| abstract_inverted_index.stress | 47, 120, 162 |
| abstract_inverted_index.strong | 138 |
| abstract_inverted_index.weeks, | 83 |
| abstract_inverted_index.weight | 21 |
| abstract_inverted_index.Insulin | 153 |
| abstract_inverted_index.TNF-α, | 148 |
| abstract_inverted_index.between | 141 |
| abstract_inverted_index.carries | 15 |
| abstract_inverted_index.clearly | 245 |
| abstract_inverted_index.control | 68 |
| abstract_inverted_index.daily). | 110 |
| abstract_inverted_index.glucose | 25 |
| abstract_inverted_index.groups, | 208 |
| abstract_inverted_index.improve | 252 |
| abstract_inverted_index.include | 20 |
| abstract_inverted_index.insulin | 142, 224, 260 |
| abstract_inverted_index.levels, | 26 |
| abstract_inverted_index.manner. | 185 |
| abstract_inverted_index.markers | 121, 131, 181 |
| abstract_inverted_index.results | 244 |
| abstract_inverted_index.stress, | 254 |
| abstract_inverted_index.suggest | 246 |
| abstract_inverted_index.vitamin | 202 |
| abstract_inverted_index.whereas | 84 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Further, | 136 |
| abstract_inverted_index.However, | 12 |
| abstract_inverted_index.addition | 104 |
| abstract_inverted_index.ascorbic | 199 |
| abstract_inverted_index.atypical | 3 |
| abstract_inverted_index.balance. | 30 |
| abstract_inverted_index.coenzyme | 197 |
| abstract_inverted_index.effects. | 18 |
| abstract_inverted_index.elevated | 24 |
| abstract_inverted_index.however, | 174 |
| abstract_inverted_index.impaired | 127 |
| abstract_inverted_index.involved | 60 |
| abstract_inverted_index.markers, | 193 |
| abstract_inverted_index.positive | 139 |
| abstract_inverted_index.possible | 157 |
| abstract_inverted_index.received | 75, 89 |
| abstract_inverted_index.results. | 241 |
| abstract_inverted_index.sulphate | 97 |
| abstract_inverted_index.taurine, | 196 |
| abstract_inverted_index.(HOMA-IR) | 145 |
| abstract_inverted_index.(received | 70 |
| abstract_inverted_index.Following | 111 |
| abstract_inverted_index.diseases. | 11 |
| abstract_inverted_index.disrupted | 28 |
| abstract_inverted_index.increased | 117 |
| abstract_inverted_index.metabolic | 42, 216, 256 |
| abstract_inverted_index.oxidative | 29, 46, 161, 253 |
| abstract_inverted_index.recovered | 177 |
| abstract_inverted_index.treatment | 53, 112 |
| abstract_inverted_index.assessment | 233 |
| abstract_inverted_index.indicators | 217 |
| abstract_inverted_index.olanzapine | 76, 106, 267 |
| abstract_inverted_index.resistance | 143, 154, 225 |
| abstract_inverted_index.widespread | 166 |
| abstract_inverted_index.Olanzapine, | 1 |
| abstract_inverted_index.Remarkably, | 204 |
| abstract_inverted_index.antioxidant | 130 |
| abstract_inverted_index.biochemical | 228 |
| abstract_inverted_index.combination | 207 |
| abstract_inverted_index.completion, | 113 |
| abstract_inverted_index.correlation | 140 |
| abstract_inverted_index.homeostatic | 192 |
| abstract_inverted_index.improvement | 213 |
| abstract_inverted_index.significant | 212 |
| abstract_inverted_index.Improvements | 186 |
| abstract_inverted_index.cholesterol) | 222 |
| abstract_inverted_index.dyslipidemia | 219 |
| abstract_inverted_index.environment. | 168 |
| abstract_inverted_index.histological | 232 |
| abstract_inverted_index.inflammation | 44 |
| abstract_inverted_index.inflammatory | 167 |
| abstract_inverted_index.perturbation | 257 |
| abstract_inverted_index.resistance), | 261 |
| abstract_inverted_index.(dyslipidemia | 258 |
| abstract_inverted_index.antipsychotic | 4 |
| abstract_inverted_index.disturbances, | 43 |
| abstract_inverted_index.dyslipidemia, | 23 |
| abstract_inverted_index.inflammation, | 255 |
| abstract_inverted_index.manifestation | 158 |
| abstract_inverted_index.psychological | 10 |
| abstract_inverted_index.respectively, | 102 |
| abstract_inverted_index.significantly | 251 |
| abstract_inverted_index.dose-dependent | 184 |
| abstract_inverted_index.intervention). | 72 |
| abstract_inverted_index.investigation. | 63 |
| abstract_inverted_index.(triglycerides, | 220 |
| abstract_inverted_index.supplementation | 249 |
| abstract_inverted_index.coadministration | 39 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 8 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7599999904632568 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.84658125 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |